ASP Isotopes Previews Q2 Results, Sets $330M-$700M 2031 EBITDA Target, and Flags Helium Production by September
ASPI sits 21% above its 52-week low of $3.51.
Summary
ASP Isotopes issued a shareholder letter previewing Q2 2026 results, forecasting PET Labs revenue of ~$14M (up from $6M), helium production by September 30, and a 2031 EBITDA target of $330M-$700M. The update provides concrete timelines and financial targets that reduce uncertainty around the company's transition to commercial production.
Key Events · Earnings and Guidance · ASPI
-
PET Labs Revenue Surge
1H 2026 organic revenue growth exceeded 50%, with FY 2026 revenue forecast at ~$14M, up from $6M in 2025. The division is on track toward a $50-100M EBITDA target by 2031.
-
Helium Production Imminent
Renergen expects to commence helium production before September 30, 2026. Phase 1 annualized helium and LNG revenues are projected at ~$27M, with Phase 2 construction starting in 2H 2026 and potential annual revenues exceeding $360M at nameplate capacity.
-
2031 EBITDA Target Set at $330M-$700M
Management provided long-term aspirational EBITDA targets of $330M-$700M by 2031, driven by radiopharmaceuticals, electronic gases, and natural gas, excluding nuclear fuels.
-
Stable Isotope Shipments in 2H 2026
Silicon-28 and Ytterbium-176 enrichment facilities are in final stages of commercial production, with initial product shipments expected in the second half of 2026. Carbon-14 enrichment is also expected to begin upon receipt of feedstock.
Analysis · ASPI · Industrial Applications And Services
The shareholder letter provides the first detailed operational update since the Q1 10-Q, revealing that PET Labs revenue is on track to nearly triple to $14M in 2026, Renergen helium production will start within two months, and the company is targeting $330M-$700M in EBITDA by 2031. These disclosures materially de-risk the near-term revenue ramp and validate the sum-of-the-parts thesis, especially against a backdrop of prior cash burn and covenant breaches. The letter also quantifies Phase 2 helium economics (>$360M annual revenue potential) and outlines a clear path to separate listings for Noble Africa and QLE, which could unlock significant value.
At the time of this filing, ASPI was trading at $4.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $521.2M. The 52-week trading range was $3.51 to $14.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.